Leerink Partnrs Reiterates "Market Perform" Rating for Morph

Leerink Partnrs reissued their market perform rating on shares of MorphoSys (NASDAQ:MOR – Free Report) in a research report report published on Wednesday morning, PriceTargets.com reports. Leerink Partnrs also issued estimates for MorphoSys’ FY2026 earnings at ($0.78) EPS. Other research analysts have also issued research reports about the company. The Goldman Sachs Group cut their […]

Related Keywords

United States , Leerink Partnrs , Morgan Stanley , Citadel Advisors , Virtu Financial , Jpmorgan Chase Co , Optiver Holding , Goldman Sachs Group , T Rowe Price Investment Management Inc , Free Report , Get Free Report , Price Investment Management , Morphosys Daily , Morphosys , Nasdaq Mor , Humor , Medical , Reiterated Rating ,